NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Great points Red. I think Direct appeals to a lot of factions.

1. Patients -- Personalization, relative ease of administration, lack of side effects, improved well being, affordable and possible lifetime immunity for many individuals.

2. Oncologists -- Ease of administration, safety, efficacy, patient well being, a hybrid transition from their chemotherapy income (not to be cynical), a hybrid transition from their surgical income (not to be cynical).

3. Insurance companies -- Predictability, reduced overall annual cost, reduces surgery and chemotherapy costs, reduced home care, reduced hospital cost.

4. Government -- Reduced work loss time/Increased productivity, eventual reduction in healthcare costs and death benefit costs. Keeps medical infrastructure (jobs) in place with smooth transition. Provides manufacturing jobs.

5. Pharmaceutical companies -- Does not immediately eliminate need for some chemotherapies and other current Big pharma income streams because the tumors often need to be softened up initially. As you mention, ultimately this will allow next generation off-the-shelf-products to provide choices and competition.

6. FDA -- Safety, efficacy, and smooth "hybrid" transition away from chemotherapy.

7. Radiologists -- Image guided injection business (not to be cynical), initial softening up will still be required in many cases.